Literature DB >> 1290272

Anti-Ro autoantibody with cross-reactive binding to the heavy chain of immunoglobulin G.

M J Mamula1, J B Harley.   

Abstract

Autoantibodies directed at the intracellular Ro ribonucleoprotein complex are found in the serum of patients with systemic lupus erythematosus (SLE) and related autoimmune diseases. The antigenic stimulus for the induction of these autoantibodies is unknown, although we have previously demonstrated that the Ro protein and immunoglobulin G (IgG) share immunologic determinants bound by anti-Ro antibodies. The present study further defines the fine specificity of this cross-reactive binding. Using both patient autoanti-Ro antibodies and antigen-induced rabbit anti-Ro serum, the binding specificity for IgG was located to the heavy chains of IgG outside the Fc domain. F(ab')2 fragments of IgG were observed to inhibit specific Ro binding by either human or antigen-induced rabbit sera, while Fc fragments of IgG failed to inhibit Ro binding. Anti-Ro sera were found to bind the heavy chains of IgG in immunoblots, and the antibodies eluted from these heavy chains were capable of immunoprecipitating the Ro particle from human cell extracts. Not all patient sera with anti-Ro antibodies possessed IgG binding antibodies. Studies of cyanogen bromide digestion fragments of IgG implicate the hinge region of IgG as the region cross-reactive with the Ro protein. The nature of this cross-reactivity may be important in understanding the induction and/or perpetuation of the anti-Ro response in patients with autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1290272      PMCID: PMC2589586     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  23 in total

1.  Precipitating autoantibodies in Sjogren's disease.

Authors:  J R ANDERSON; K G GRAY; J S BECK; W F KINNEAR
Journal:  Lancet       Date:  1961-08-26       Impact factor: 79.321

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  Isolation and characterization of active fragments obtained by cleavage of immunoglobulin G with cyanogen bromide.

Authors:  J H Cahnmann; R Arnon; M Sela
Journal:  J Biol Chem       Date:  1966-07-25       Impact factor: 5.157

4.  Certain rheumatoid factors react with nucleosomes.

Authors:  K Hannestad; B D Stollar
Journal:  Nature       Date:  1978-10-19       Impact factor: 49.962

5.  Methods and applications of hapten-sandwich labeling.

Authors:  L Wofsy
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

6.  The Ro ribonucleoprotein particle: induction of autoantibodies and the detection of Ro RNAs among species.

Authors:  M J Mamula; C A O'Brien; J B Harley; J A Hardin
Journal:  Clin Immunol Immunopathol       Date:  1989-09

7.  Naturally occurring human antibodies to the F(ab')2 portion of IgG.

Authors:  H Nasu; D S Chia; D W Knutson; E V Barnett
Journal:  Clin Exp Immunol       Date:  1980-11       Impact factor: 4.330

8.  Molecular analysis of the 60-kDa human Ro ribonucleoprotein.

Authors:  S L Deutscher; J B Harley; J D Keene
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

9.  The Ro small cytoplasmic ribonucleoproteins: identification of the antigenic protein and its binding site on the Ro RNAs.

Authors:  S L Wolin; J A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

10.  A 52-kD protein is a novel component of the SS-A/Ro antigenic particle.

Authors:  E Ben-Chetrit; E K Chan; K F Sullivan; E M Tan
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

View more
  1 in total

1.  Association of neutropenia in systemic lupus erythematosus (SLE) with anti-Ro and binding of an immunologically cross-reactive neutrophil membrane antigen.

Authors:  B T Kurien; J Newland; C Paczkowski; K L Moore; R H Scofield
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.